Real-World Evidence: Sanofi Push Driven By Aetion Deal
Facilitating Regulatory-Grade Clinical Studies
Executive Summary
Sanofi and US start-up Aetion are to collaborate on integrating their real-world evidence and analytics platforms to improve the clinical development process.
You may also be interested in...
Sanofi's Dupixent To Keep Soaring Despite NICE Blip
NICE is not recommending Dupixent for severe asthma just yet but Sanofi remains confident of hitting its sales target of €10bn a year.
ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.